Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept + FOLFIRI in 1st line metastatic colorectal cancer
NCT02181556Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Oct 2014
- Primary completion
- Feb 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in colorectal cancer (metastatic) (mCRC), sponsored by Fédération Francophone de Cancérologie Digestive. Started Oct 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT02181556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02181556.